In this industry-sponsored phase-3 trial of patients with skin/skin-structure infections or catheter-related bloodstream infections with gram positive organisms, linezolid was non-inferior to vancomycin. For skin infections, clinical success rates were 90% in each group. For catheter related bloodstream infections, microbiologic success rates were 86% for linezolid and 91% for vancomycin (abstract). Linezolid is currently FDA approved to treat VRE infections, as well as pneumonia (nosocomial and community-acquired) and skin/skin-structure infections caused by resistant gram-positive organisms (FDA sheet). Based on this study, it can reasonably be used for resistant gram-positive bacteremia, when vancomycin cannot be used.
by Deepak Asudani, MD, MPH, FHM Whether it is the prompt and expeditious international collaboration to develop an Ebola vaccine, or tardy but promising development of the first anti parasitic malarial vaccine or the fascinating technology utilizing synthetic DNA for vaccine development against MERS, these developments promise to highlight significant strides in vaccine development for […]
Economists describe preferences in two ways: revealed and stated. Say, for example, I asked you to implement a penalty program for your team with the goal of decreasing the number of occasions members did not clean their hands after a patient encounter. Because you know bad hands equal bad outcomes, you’re apt to offer up […]
by Eric Howell, MD, SFHM “Tell me what you know about antibiotics.” That’s the discussion I start with hospitalized patients all the time, right after they ask me to prescribe antibiotics for their simple cough, or other viral-like illness. And, from their perspective, asking for antibiotics makes sense. After all, antibiotics have been the physician’s […]